PDE4A and respiratory tract infectious disorder: The use of anti-inflammatory therapeutics against NTHi respiratory infection has been previously tested in vivo for dexamethasone, azithromycin and the non-bactericidal PDE4 inhibitors roflumilast N-oxide and rolipram, highlighting the benefits of PDE4 inhibition22–24,38.